RxDoctor Payments Data

Jesse Hochkeppel, MD

Pain Medicine · Danbury, CTNPI 1609142694

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Boston Scientific at 59.9% of the total. Reporting peaked in 2023 at $546 and has fallen 68.4% since, to $172 in 2025. That places this record below the midpoint for pain medicine clinicians in CT, where the typical reported total is $2,061.

$2,061in general payments, 2019–2025

Across 55 payments — averaging $37.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Nevro Corp.$198
  • Saluda Medical Americas, Inc.$168
  • Epimed International, Inc$128
  • Abbott$92
  • DJO, LLC$60
  • plus $182 from 6 others

What the payments were for

  • Food & beverage$2,061100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,061 in reported general payments places this provider in the 50th percentile of 69 pain medicine providers in Connecticut.

See all pain medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$565,256
Medicare patients
545
Services billed
29,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl84$48,716
Xtampza ErOxycodone Myristate81$45,354
Oxycodone Hcl624$11,032
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen391$6,950
Gabapentin585$6,362
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen220$5,498
Buprenorphine12$4,699
Pregabalin254$4,512
Morphine Sulfate ErMorphine Sulfate110$4,050
Tramadol Hcl499$3,657
Morphine Sulfate78$3,089
ButransBuprenorphine12$2,902
Lidocaine22$2,699
Fentanyl11$1,816
Methocarbamol115$1,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$38$45,35481 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 69 pain medicine providers in Connecticut.

Other pain medicine in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →